Outpace Bio

Outpace Bio

Private
Seattle, WashingtonHealthcare & Life Scienceshttps://www.outpacebio.com

Last Round

Series B

Aug 1, 2024

Total Funding Raised

$174M

Company Overview

Outpace Bio is a biotechnology company that develops innovative cell therapies to enhance the safety and effectiveness of gene therapies through AI-powered protein design and cellular control modalities.

Sector

Healthcare & Life Sciences

Verticals

Biotechnology, Drug Discovery, Medical AI, Clinical Trials, Precision Medicine

Business Model

B2B

Customer Profile

Services & Consulting, Revenue Share

AI Layer

Application

Keywords

computational protein designcell therapysolid tumorsCAR-T therapyAI protein designsynthetic biologyprotein engineeringnext generation cell therapiesprogrammable medicinedrug discovery platformimmunotherapyde novo protein designbiotech partnershipstumor microenvironmentoncology

Historical Pricing

Historical view of private secondary pricing and transaction trends.

Unlock Pricing Charts

Sign up to view complete historical pricing and secondary transactions.

Caplight Momentum Score

Proprietary index based on bid/ask volume and sentiment.

View Momentum History

Track how buyer interest and sentiment changes over time.

Outpace Bio Comps

Public and private peers based on sector, stage, and business model.

CompanyStatusEst. ValuationRev Multiple
OpenAIPrivate$86.0B~40x
CoherePrivate$5.0B--
Competitor 1Public$XX.XBXXx
Competitor 2Public$XX.XBXXx

View Full Comps Set

Access detailed peer comparisons, multiples, and valuation benchmarks.

Outpace Bio Funding Rounds

Historical fundraising activity

RoundDateAmount RaisedValuationInvestorsSources
Series BAug 1, 2024
Series AMar 31, 2021

Key People

Founding team and executive leadership

Scott Boyken

Co-Founder, Chief Technology Officer

Founding Team

Marc Lajoie

Co-founder, Chief Executive Officer

Founding Team

Outpace Bio Investors

Notable investors and investment history

InvestorRounds
RA Capital ManagementSeries B
WRF CapitalSeries A, Series B
Playground GlobalSeries A, Series B
ARTIS VenturesSeries B, Series A
Surveyor CapitalSeries B
Washington Research Foundation CapitalSeries A, Series B
Abstract VenturesSeries A, Series B

Market signals

Structured signals derived from secondary market and firmographic data.

  • Nov 4, 2025

    Lead candidate OPB-101 targeting ovarian cancer to begin dosing in 2025.

Outpace Bio Filings

SEC and related filings with document metadata.

TypedDateAmount OfferedAmount SoldFillingPagesDownload
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation

Outpace Bio Filings

SEC and related filings with document metadata.

Frequently Asked Questions

Common questions about Outpace Bio's valuation, stock price, and market status.

Firmographic Details

HeadquartersSeattle, Washington
Employee Range71
Year Founded2020
Last FundingAug 1, 2024

Institutional Data Access

Join leading institutional investors using Caplight to access private market data, discover pricing, and execute secondary block trades.

Requires verified institutional or accredited status.







Disclaimer All investments involve risk, including the risk of loss of principal. You should carefully consider your investment objectives, risks, transaction costs and other expenses before deciding to invest in options, swaps or other investments.This does not constitute an offer by Caplight Technologies, Inc. to sell, or a solicitation of an offer to buy, any securities and may not be used or relied upon in connection with any offer or sale of securities. An offer or solicitation can be made only through the delivery of final offering document(s) and purchase agreement(s), and will be subject to the terms and conditions and risks delivered in such documents. Any securities offered are offered through Caplight Markets LLC, member FINRA/SIPC.